XML 31 R20.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Dec. 31, 2018

Stockholders' Equity Note [Abstract]

Summary of weighted-average assumptions used to estimate the fair values of the stock options granted

The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:

		Enochian Biosciences Inc.
Expected term (in years)			3-10
Volatility			94.37-98.15	%
Risk free interest rate			3.06-3.23	%
Dividend yield			0	%

Summary of stock options outstanding

A summary of the status of the Plan Options and Grant Warrants outstanding at December 31, 2018 is presented below:

Options Outstanding												Options Exercisable
		Exercise Prices				Number Outstanding				Weighted Average Remaining Contractual Life (years)				Weighted Average Exercise Price				Number Exercisable			Weighted Average Exercise Price
		$	8.00				69,235				9.32			$	8.00				-			-
			5.74				15,679				9.72				5.74				-			-
			3.95				5,064				9.54				3.95				-			-
			2.00				650,000				1.00				2.00				650,000			2.00
			5.72				13,113				9.84				5.72				-			-
		$	6.50				300,000				9.90			$	6.50				300,000		$	6.50
Total			-				1,053,091				4.36			$	3.79				950,000		$	3.42

Summary of stock option activity

A summary of the status of the Plan Options and the Grant Warrants at December 31, 2018 and changes during the period are presented below:

		Shares				Weighted Average Exercise Price				Average Remaining Life				Weighted Average Intrinsic Value

Outstanding at beginning of period			690,621			$	2.00				2.50			$	-
Granted			362,470				6.52				10				-
Exercised			-				-				-				-
Forfeited			-				-				-				-
Expired			-				-				-				-
Outstanding at end of period			1,053,091			$	3.79				4.36			$	3,451,984
Vested and expected to vest			950,000			$	3.42				3.81			$	3,400,000
Exercisable end of period			950,000			$	3.42				3.81			$	3,400,000

Summary of common stock purchase warrants outstanding

A summary of the status of shares of Common Stock which can be purchased underlying the warrants outstanding at December 31, 2018 is presented below:

		Shares				Weighted Average Exercise Price				Weighted Average Remaining Life

Outstanding at beginning of period			5,838,122			$	1.33				-
Granted			-				-				-
Exercised			(1,307,693	)			-				1.30
Cancelled/Expired			-				-				-
Outstanding at end of period			4,530,429			$	1.30				3.38
Exercisable end of period			4,530,429			$	1.30				3.34

Summary of common stock purchase warrants

			Equivalent Shares Underlying Warrants Outstanding												Equivalent Shares Exercisable
Exercise Prices			Equivalent Shares				Weighted Average Remaining Contractual Life (years)				Weighted Average Exercise Price				Number Exercisable					Weighted Average Exercise Price
$	1.30			4,505,429			3.37				$	1.30				4,505,429		$	1.30
$	8.00			25,000			2.12				$	8.00				25,000		$	8.00

	Total			4,530,429			3.37				$	1.34				4,530,429		$	1.34

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details